English Korean Chinese
ホーム > ニューズレター > 医薬品 > Cancer Drug News
ニューズレターカテゴリ
バイオテクノロジー (11)
医薬品 (28)
医療機器 (7)
通信/IT (62)
電子部品/半導体 (7)
自動車 (5)
エネルギー (7)
環境 (4)
防衛/航空宇宙 (7)
マテリアル (21)
産業用機械 (1)
建築/土木 (3)
金融/保険 (27)
食料/飲料 (21)
一般消費財 (12)
ニューズレター

Cancer Drug News

発行 Espicom Business Intelligence
発行回数 44 回/年 商品コード 4201
ページ情報 英文  
価格
US$ 1,080 換算 ¥ 86,918 (税抜) 1 Year Web Access (Single User License)
US$ 1,080 換算 ¥ 86,918 (税抜) 1year Hard Copy
US$ 1,080 換算 ¥ 86,918 (税抜) 1year PDF by e-mail


原文目次

Monitoring business developments in world anticancer drug markets is becoming more and more vital as cancer, in all its guises, remains one of the most resistant conditions, and its position in the pharmaceutical industry is assured.

In an effort to stay in touch with the companies, products, alliances and research that are shaping the global cancer market, Espicom has launched this major new publication.

Cancer Drug News (CDN) can save you the time and effort of ensuring you have the necessary information to keep up-to-date with the developments in this world market. Incorporating primary resource material augmented with data from Espicom's unique intelligence base, CDN provides a compelling, easy-to-read route to complete market knowledge.

The following sections appear in every issue:

  • Therapies for Cancer-Related Complications
  • General Development News
  • Conference Listings

A selection of the following topics will appear each month, depending on news availability:

  • Breast Cancer
  • Haematological Cancers
  • Liver Cancer
  • Gastro-Intestinal Cancers
  • Lung Cancer
  • Gynaecological Cancers
  • Genito-Urinary Cancers
  • Brain Tumours
  • Head and Neck Cancers
  • Melanoma/Sarcoma
Back to Top